EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy

Changlin Zhen, Xunxun Wu, Jing Zhang, Dan Liu, Guoli Li, Yongbo Yan, Xiuzhen He, Jiawei Miao, Hongxia Song, Yifan Yan, Yonghui Zhang

Frontiers in Pharmacology · 23.03.2023 · 14

DOI: 10.3389/fphar.2023.1127123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.03.2023. Verfasst von Changlin Zhen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathological cardiac hypertrophy is an important risk factor for cardiovascular disease. However, drug therapies that can reverse the maladaptive process and restore heart function are limited. Ganoderma lucidum polysaccharides (GLPs) are one of the main active components of G. lucidum ( Ganoderma lucidum ), and they have various pharmacological effects. GLPs have been used as Chinese medicine prescriptions for clinical treatment. In this study, cardiac hypertrophy was induced by transverse aortic constriction (TAC) in mice. We found that GLPs ameliorate Ang II-induced cardiomyocyte hypertrophy in vitro and attenuate pressure overload–induced cardiac hypertrophy in vivo . Further research indicated that GLPs attenuated the mRNA levels of hypertrophic and fibrotic markers to inhibit cardiac hypertrophy through the PPARγ/PGC-1α pathway. Overall, these results indicate that GLPs inhibit cardiac hypertrophy through downregulating key genes for hypertrophy and fibrosis and attenuate pressure overload-induced pathological cardiac hypertrophy by activating PPARγ. This study provides important theoretical support for the potential of using GLPs to treat pathological myocardial hypertrophy and heart failure.

Schlagwörter

Stichwörter der Autor:innen

GLPsPGC-1αPPARγcardiac hypertrophyheart function

Autor:innen und Institutionen

  • Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing, China.
  • Chongqing Engineering Research Center of Antitumor Natural Drugs, Chongqing Three Gorges Medical College, Chongqing, China.
  • School of Biomedical Science, Huaqiao University, Quanzhou, China.
  • The People's Hospital Affiliated to Chongqing Three Gorges Medical College, Chongqing, China.

Zitieren

APA

Zhen, C., Wu, X., Zhang, J., Liu, D., Li, G., Yan, Y., He, X., Miao, J., Song, H., Yan, Y., & Zhang, Y. (2023). Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1127123

Vancouver

Zhen C, Wu X, Zhang J, Liu D, Li G, Yan Y, et al. Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1127123

BibTeX
@article{Zhen2023,
  author = {Zhen, Changlin and Wu, Xunxun and Zhang, Jing and Liu, Dan and Li, Guoli and Yan, Yongbo and He, Xiuzhen and Miao, Jiawei and Song, Hongxia and Yan, Yifan and Zhang, Yonghui},
  title = {Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1127123}
}
Kostenlos starten →